NCT04380805已完成2 期
A Phase 2, Multicenter, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects With Recurrent or Metastatic Cervical Cancer
Akeso25 个研究点 分布在 3 个国家目标入组 30 人开始时间: 2020年7月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 25
- 主要终点
- Objective response rate (ORR) assessed by Independent Radiological Review Committee (IRRC)
研究概览
简要总结
This is a Phase 2, global, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic cervical carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Able to provide written and signed informed consent and any locally required authorization obtained from the subject/legal representative.
- •Women aged ≥18 years at the time of study entry.
- •Subjects must have histologically or cytologically confirmed recurrent or metastatic squamous carcinoma or adenosquamous carcinoma of the cervix, and meet the following criteria: disease progression confirmed by radiologic imaging during or following prior platinum based doublet chemotherapy, with or without bevacizumab for recurrent or metastatic cervical cancer; No more than 2 prior systemic therapies in the recurrent or metastatic setting.
- •Subjects must have measurable lesions according to RECIST v1.
- •The presence of measurable lesions must be confirmed by the IRRC. A previously irradiated lesion is not considered measurable and cannot be selected as a target lesion.
- •Available archived tumor tissue sample - block or a minimum of 10 unstained slides of formalin fixed paraffin embedded [FFPE] tissues - preferably from the most recent biopsy of a tumor lesion collected either at the time of or after the diagnosis of locally advanced, recurrent, and/or metastatic disease has been made.
- •Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or
- •Life expectancy ≥12 weeks.
- •Adequate organ function.
排除标准
- •Concurrent enrollment in another clinical study, unless it is an observational (noninterventional) clinical study or the follow-up period of an interventional study.
- •Histological types of cervical cancer other than squamous carcinoma and adeno-squamous carcinoma (eg, adenocarcinoma, small cell carcinoma, clear cell carcinoma, sarcoma, etc).
- •Prior malignancy active within the previous 2 years except for the tumor for which a subject is enrolled in the study, and locally curable cancers that have been apparently cured, such as basal cell skin cancer, or carcinoma in situ of the breast.
- •Brain/central nervous system (CNS) metastases.
- •Clinically significant hydronephrosis, as determined by the investigator, not alleviated by nephrostomy or ureteral stent
- •Active infections (including tuberculosis) requiring systemic antibacterial, antifungal, or antiviral therapy within 4 weeks prior to the first dose of investigational product.
- •Known history of testing positive for human immunodeficiency virus (HIV) or known active acquired immunodeficiency syndrome.
- •Known active hepatitis B or C infections (known positive hepatitis B surface antigen [HBsAg] result or positive hepatitis C virus [HCV] antibody with detectable HCV ribonucleic acid [RNA] results).
- •Active or prior documented autoimmune disease that may relapse.
- •History of interstitial lung disease or noninfectious pneumonitis, except for those induced by radiation therapies.
- •Patients with clinically significant cardio-cerebrovascular disease.
- •Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1, or to levels dictated in the eligibility criteria with the exception of toxicities not considered a safety risk.
- •History of severe hypersensitivity reactions to other mAbs.
- •Prior allogeneic stem cell transplantation or organ transplantation.
- •Known allergy or reaction to any component of the AK104 formulation.
- •Receipt of the following treatments or procedures: anticancer small molecule targeted agent within 2 weeks, radiation therapy within 2 weeks, other anticancer therapy within 4 weeks, any major surgery within 4 weeks, any other investigational product or procedure within 4 weeks, or agents with immunomodulatory effect within 2 weeks prior to the first dose of investigational product.
- •Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily doses of prednisone or equivalent) or other immunosuppressive medications within 14 days prior to the first dose of investigational product.
- •Receipt of live attenuated vaccines within 30 days prior to the first dose of investigational product.
- •Prior exposure to any experimental antitumor vaccines, or any agent targeting T-cell costimulation or immune checkpoint pathways (eg, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, anti-CD137 or anti-OX40 antibody, etc).
- •Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.
研究组 & 干预措施
AK104
Experimental
AK104 monotherapy
干预措施: AK104 (Biological)
结局指标
主要结局
Objective response rate (ORR) assessed by Independent Radiological Review Committee (IRRC)
时间窗: Up to 2 years
次要结局
- ORR assessed by Investigator(Up to 2 years)
- Number of subjects who develop detectable anti-drug antibodies(From first dosing date of AK104 through 90 days post last dose of AK104, up to 2 years)
- Minimum observed concentration (Cmin) of AK104 at steady state(From first dosing date of AK104 through 30 days post last dose of AK104, up to 2 years)
- Disease control rate (DCR)(Up to 2 years)
- Duration of Response (DoR)(Up to 2 years)
- Progression-free survival (PFS)(Up to 2 years)
- Number of participants with adverse events (AEs)(From the time of informed consent signed through 30 days after the last dose, up to 2 years)
研究者
研究点 (25)
Loading locations...
相似试验
进行中（未招募）
2 期
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)Lymphoma, Non-HodgkinNCT04245839Celgene276
Unknown
2 期
A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCLRR DLBCL; PD-1; CD20NCT05178836Shandong New Time Pharmaceutical Co., LTD62
尚未招募
2 期
A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)PD-1Non-small Cell Lung CancerNSCLCNCT05741021Shandong New Time Pharmaceutical Co., LTD84
终止
2 期
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaGastroesophageal Junction AdenocarcinomaGastric CancerNCT06206278LianBio LLC6
招募中
2 期
Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic LeukemiaRelapsed/Refractory Large Granular T Lymphocytic LeukemiaNCT06224257Institute of Hematology & Blood Diseases Hospital, China41